ArticleJournal of thoracic disease2025
Survival outcome after systematic lymphadenectomy in non-small cell lung cancer according to the latest proposed edition of the TNM system.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: While systematic lymphadenectomy (SLND) provides critical information for accurate staging, its direct impact on survival outcomes remains unclear and subject to ongoing debate. This study presents survival outcomes across various nodal stages to clarify the potential role of SLND in improving prognosis. SLND is routinely performed during the resection of non-small cell lung cancer (NSCLC) to assess lymph node involvement and determine the nodal stage. Methods: We retrospectively analyzed data from 367 patients who underwent curative surgery for NSCLC between 2008 and 2019. The Chi-squared test has been employed to compare the distribution of categorical variables between groups. We used a Cox proportional hazards regression model for multivariable survival analysis to identify independent prognostic factors, including sex, histologic type, N factor, and type of surgical procedure. We evaluated these variables based on 5-year post-surgery survival rates. Additionally, we used the log-rank test and Kaplan-Meier curve analysis. Results: In 367 patients (228 male and 139 female), SLND was performed. Out of these patients were N0 (n=267, 72.8%), N1 (n=61, 16.6%) and N2 (n=39, 10.6%). The overall 5-year survival rate for the entire cohort was 54.2%. There was a significant difference in survival rates between genders (P<0.001). Females showed a higher survival rate (69.1%) than males (45.2%). The 5-year survival is 66% for stage I (P<0.001) and 33.9% for stage IIA (P<0.001) in NSCLC patients. The multi-level N1 situation did not significantly affect survival (44.4%, P=0.66). The multi-level N2 was associated with a much lower survival rate of 10.0% (P<0.001). An analysis of each lymph node revealed that the paraesophageal group (Group 8) had a survival rate of 14.3% (P<0.001). Conclusions: Our study indicates that SLND does not directly impact 5-year survival rates, particularly in early-stage NSCLC. However, SLND may play a critical role in achieving accurate tumor staging, which is essential for guiding subsequent treatment strategies. Despite its utility in staging, the current staging system demonstrates variability in predicting survival outcomes, especially when considering specific N stages or nodal groups involved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.